Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

TH QUARTER ENDED DECEMBER 31, 2007

Consolidated revenues were $10.2 million for the fourth quarter ended December 31, 2007 compared to $11.9 million for the same quarter in 2006. The decrease in revenues is attributable to lower sales of Impavido(R), as well as active pharmaceutical ingredients to the Company's partners, combined with lower license fees from the Company's partners.

Selling, General and Administrative (SG&A) expenses were $5.1 million for the fourth quarter ended December 31, 2007 compared to $4.2 million for the same quarter in 2006. The increase in SG&A is mainly related to the support of the continuation of a Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH) and the opening of a new operational headquarters in New Jersey.

Consolidated Research & Development (R&D) expenses were $13.6 million for the fourth quarter ended December 31, 2007 compared to $7.9 million for the same quarter in 2006. The increase in R&D expenses relates to the continuation of the Company's Phase 3 program with cetrorelix in BPH.

Consolidated net loss was $13.6 million or $0.26 per basic and diluted share for the fourth quarter ended December 31, 2007 compared to consolidated net earnings of $39.1 million or $0.74 per basic and diluted share for the same quarter in 2006. The increased net loss in the fourth quarter 2007 is related to higher loss from operations of nearly $5.2 million mainly related to increased R&D expenses, as well as to lower income tax recovery of nearly $28.4 million attributable to the recognition of future income tax assets mainly related to the sale of Atrium shares in 2006 and the special distribution of the Company's remaining interest in January 2007, combined with the decrease in net earnings from Atrium's discontinued operations of approximately $16.3 million.

The consolidated cash and short-term investments were $41.4 million as of December 31, 2007.

CONSOLIDATED RESULTS FOR THE FULL
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Madison, WI (PRWEB) May 24, 2013 ... to the discovery and development of calcium-binding proteins ... publication of safety assessment study of apoaequorin ... an international journal published for the British Industrial ... the study was to investigate potential adverse effects, ...
(Date:5/23/2013)... Can economic incentives such as gift cards, ... the public to increase their donations of blood? , ... Business School Assistant Professor Mario Macis says the ... body of recent research that supports their argument, the ... of Science that the World Health Organization and national ...
(Date:5/23/2013)... 2013 The maker community is a ... inventions. They focus on learning practical skills while applying ... toward bringing their ideas to life via crowdfunding. A ... on making projects using biology. Glowing Plant has worked ... make them glow with bioluminescence genes, and has now ...
(Date:5/23/2013)... 23, 2013 BioTrends Research Group, one ... for specialized biopharmaceutical issues, finds that, unaided, one ... specialists reported that in the past six months, ... treatment) in anticipation of the next generation of ... when only 6 percent reported that they had ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... Journal Indicates Masimo SET May Also Reduce the Need for ... Jan. 30 Masimo (Nasdaq: ... Motion and Low Perfusion pulse oximetry, today announced that a ... January 2009 issue of the British Medical Journal ...
... Stock Exchange Symbol: MSEDMONTON, Jan. 30 /PRNewswire-FirstCall/ - ... in the treatment of multiple sclerosis (MS), today ... clinical trial evaluating dirucotide in patients with relapsing-remitting ... is for secondary progressive MS where it is ...
... CA The logic and memory functions of future electronic ... (billionths of a meter) instead of the many tens of ... way can be found to control domain walls, the ultrathin ... magnetic, electric, or other properties. , In a ...
Cached Biology Technology:New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns 2New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns 3New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns 4New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns 5BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis 2BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis 3BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis 4BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis 5Domain walls that conduct electricity 2Domain walls that conduct electricity 3Domain walls that conduct electricity 4Domain walls that conduct electricity 5
(Date:5/23/2013)... Public Health at Emory University, along with partners ... a $4 million grant over four years to ... and Exposome Research Center: Understanding Lifetime Exposures). The ... in the United States. , The HERCULES ... Environmental Health Sciences (NIEHS) of the National Institutes ...
(Date:5/23/2013)... wrapping of genomic DNA around nucleosomes in the ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich now ... be locally displaced from nucleosomes for transcription. , ... in the cell nucleus, wrapped around disk-shaped particles ... four different histone proteins and accommodating two loops ...
(Date:5/23/2013)... unnecessarily undergo surgery or harsh treatments because science ... aggressive forms of the disease. Researchers at Case ... are developing technology that allows patients to safely ... treatments or take drastic measures. , The project ... professor of biomedical engineering at Case Western Reserve ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Biochemistry: Unspooling DNA from nucleosomal disks 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... healthy men decline as they get older. As sleep ... in the amount of sleep a healthy older man gets ... to a study published in the April 1st issue of ... MD, PhD, of the University of Chicago, focused on 12 ...
... state-of-the-art technique to map neurons in the spinal cord ... a surprising pattern of activity that regulates the speed ... implications for treating injured human spinal cords and Parkinson’s ... The study, "A Topographic Map of Recruitment in Spinal ...
... delivery system using microspheres of a biodegradable polymer may not ... but also appears to stimulate an immune response that traditional ... their findings today at the ASM Biodefense and Emerging Disease ... that block entry into the cell. In the case ...
Cached Biology News:Fast and slow -- How the spinal cord controls the speed of movement 2Biodegradable microspheres deliver time release vaccines, stimulate different immune response 2
... InnoScan700 is a fluorescence scanner with ... biochip (Staggered/Orange Packing, Protein, CGH, ) spotted ... the range of InnoScan700 scanners include three ... InnoScan700A is a simultaneous dual fluorescence scanner ...
... neurons in vesicles called synaptosomes. ... bouton. Synaptosomes may be centrifuged ... cellular debris. Abnormalites in neurotransmitter release ... condtions. Conditions of release may ...
... Frame DNAscope is an integrated confocal laser ... readily integrated into your specific application. GeneFocus ... can tailor the system to your specifications. ... scanning design has been modularized and built ...
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...
Biology Products: